A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

NCT04672928 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG: paclitaxel
DRUG: IBI318

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.